Silvennoinen, R
Anttila, P
Säily, M
Lundan, T
Heiskanen, J
Siitonen, T M
Kakko, S
Putkonen, M
Ollikainen, H
Terävä, V
Kutila, A
Launonen, K
Räsänen, A
Sikiö, A
Suominen, M
Bazia, P
Kananen, K
Selander, T
Kuittinen, T
Remes, K
Jantunen, E
Article History
Received: 17 June 2015
Revised: 17 August 2015
Accepted: 19 August 2015
First Online: 5 October 2015
Competing interests
: RS has received a research grant from Celgene and Janssen and honoraria from Genzyme and Sanofi. EJ has received honoraria from Genzyme and Sanofi and has participated in an EU Leadership meeting organized by Genzyme as well as a Medical Advisory Board meeting organized by Genzyme. KR has received Advisory Board honoraria from Celgene, Janssen and Roche. MP has received Advisory Board honoraria from Amgen and Celgene. KK has received honoraria from Amgen, Roche and Fresenius and educational travel grants from Amgen and Hospira. AR has participated in Advisory Boards organized by Amgen and Roche. MS has received educational travel grants from Celgene, Genzyme and Pfizer. KL has received educational travel grants from Celgene, Mundipharma and Novartis. The remaining authors declare no conflict of interest.